Skip to main content
Journal cover image

Cardiovascular and renal outcomes with combination exenatide and open-label SGLT2 inhibitor treatment in EXSCEL

Conferences
Clegg, LE; Penland, RC; Bachina, S; Boulton, DW; Thuresson, M; Heerspink, HJL; Gustavson, S; Sjostrom, CD; Ruggles, J; Hernandez, AF; Buse, JB ...
Published in: DIABETOLOGIA
September 1, 2019

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

DIABETOLOGIA

EISSN

1432-0428

ISSN

0012-186X

Publication Date

September 1, 2019

Volume

62

Start / End Page

S4 / S5

Location

Barcelona, SPAIN

Publisher

SPRINGER

Conference Name

55th Annual Meeting of the European-Association-for-the-Study-of-Diabetes (EASD)

Related Subject Headings

  • Endocrinology & Metabolism
  • 4206 Public health
  • 3202 Clinical sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Clegg, L. E., Penland, R. C., Bachina, S., Boulton, D. W., Thuresson, M., Heerspink, H. J. L., … Holman, R. R. (2019). Cardiovascular and renal outcomes with combination exenatide and open-label SGLT2 inhibitor treatment in EXSCEL. In DIABETOLOGIA (Vol. 62, pp. S4–S5). Barcelona, SPAIN: SPRINGER.
Clegg, L. E., R. C. Penland, S. Bachina, D. W. Boulton, M. Thuresson, H. J. L. Heerspink, S. Gustavson, et al. “Cardiovascular and renal outcomes with combination exenatide and open-label SGLT2 inhibitor treatment in EXSCEL.” In DIABETOLOGIA, 62:S4–5. SPRINGER, 2019.
Clegg LE, Penland RC, Bachina S, Boulton DW, Thuresson M, Heerspink HJL, et al. Cardiovascular and renal outcomes with combination exenatide and open-label SGLT2 inhibitor treatment in EXSCEL. In: DIABETOLOGIA. SPRINGER; 2019. p. S4–5.
Clegg, L. E., et al. “Cardiovascular and renal outcomes with combination exenatide and open-label SGLT2 inhibitor treatment in EXSCEL.” DIABETOLOGIA, vol. 62, SPRINGER, 2019, pp. S4–5.
Clegg LE, Penland RC, Bachina S, Boulton DW, Thuresson M, Heerspink HJL, Gustavson S, Sjostrom CD, Ruggles J, Hernandez AF, Buse JB, Mentz RJ, Holman RR. Cardiovascular and renal outcomes with combination exenatide and open-label SGLT2 inhibitor treatment in EXSCEL. DIABETOLOGIA. SPRINGER; 2019. p. S4–S5.
Journal cover image

Published In

DIABETOLOGIA

EISSN

1432-0428

ISSN

0012-186X

Publication Date

September 1, 2019

Volume

62

Start / End Page

S4 / S5

Location

Barcelona, SPAIN

Publisher

SPRINGER

Conference Name

55th Annual Meeting of the European-Association-for-the-Study-of-Diabetes (EASD)

Related Subject Headings

  • Endocrinology & Metabolism
  • 4206 Public health
  • 3202 Clinical sciences